20
Cipla Ltd, based in India, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their notable products is ABACAVIR SULFATE USP, with a corresponding US DMF Number 26299.
Remarkably, this DMF maintains an Active status since its submission on August 22, 2012, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of July 29, 2013, and payment made on March 13, 2013, indicating their dedication to facilitating drug approvals, Categorized as Type II